RonaldNathanielMarcusMD
Psychiatry • Boston, MANeuropsychiatry, Psychopharmacology
SVP at Bristol-Myers Squibb
Dr. Marcus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Karuna Therapeutics
Boston, MA 02110Phone+1 203-376-3914- Is this information wrong?
Summary
- Bristol-Myers Squibb, SVP Clinical Development in Psychiatry
Karuna Therapeutics SVP Clinical Development
Supernus - VP of R&D
Cerecor - Chief Medical Officer and Head of Regulatory Affairs
Spinifex Pharmaceuticals - Chief Medical Officer
Bristol Myers Squibb - 23 years, Executive Director Neuroscience Clinical Research
Education & Training
NewYork–Presbyterian/Westchester DivisionFellowship, NIMH - Research Training , 1987 - 1989
New York Presbyterian Hospital (Cornell Campus)/WestchesterResidency, Psychiatry, 1984 - 1987- Nassau University Medical CenterInternship, Internal Medicine, 1983 - 1984
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1983- University of VirginiaBA, Psychology, 1975 - 1979
Certifications & Licensure
MD State Medical License 2022 - 2025
CT State Medical License 1985 - 2022
NY State Medical License 1984 - 1992- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 6 citationsA proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression.Adelaide S. Robb, Stefan Schwabe, Gianpiera Ceresoli-Borroni, Azmi Nasser, Chungping Yu, Ronald N. Marcus, Shawn A. Candler, Robert L. Findling> ;Postgraduate Medicine. 2019 Feb 14
- 10 citationsEfficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.J. Craig Nelson, Zia Rahman, Kimberly K. Laubmeier, James M. Eudicone, Robert D. McQuade, Robert M. Berman, Ronald N. Marcus, Ross A. Baker, John J. Sheehan> ;CNS Spectrums. 2014 Dec 1
- Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.Casey, D. E.,Laubmeier, K. K.,Eudicone, J. M.,Marcus, R.,Berman, R. M.,Rahman, Z.,Sheehan, J.> ;Int. J. Clin. Pract.. 2014 Sep 10
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
